You haven't searched anything yet.
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients' lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on delivering oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Kymera is also progressing degrader oncology programs that target undrugged or poorly drugged proteins to create new ways to fight cancer. Founded in 2016, Kymera has been recognized as one of Boston's top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X (formerly Twitter) or LinkedIn.
You will seamlessly partner with all line functions represented on the project teams and will be accountable to set DMPK strategy and drive execution to advance projects from early discovery through preclinical development. Your deep expertise in PK/ADME strategies and tactics in small molecule drug discovery and preclinical development is foundational, and hands-on experiences in PK and PK/PD modeling will serve you well. You will thrive in a collaborative, past-paced, interdisciplinary team environment.
Kymera Therapeutics is proud to be an equal opportunity employer, seeking to create a welcoming and diverse environment. All applicants will receive consideration for employment without regard to race, color, religion, creed, gender, national origin, age, disability, veteran status, pregnancy, sex, marital status, gender expression or identity, genetic information, sexual orientation, citizenship, or any other legally protected class.
Full Time
$140k-181k (estimate)
04/04/2024
06/03/2024
kymeratx.com
Watertown, MA
50 - 100